Wall Street analysts predict that Apollo Endosurgery Inc (NASDAQ:APEN) will announce earnings per share of ($0.29) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Apollo Endosurgery’s earnings. Apollo Endosurgery posted earnings per share of ($35.01) in the same quarter last year, which indicates a positive year over year growth rate of 99.2%. The firm is expected to report its next earnings results on Wednesday, March 14th.

On average, analysts expect that Apollo Endosurgery will report full year earnings of ($1.98) per share for the current financial year, with EPS estimates ranging from ($2.10) to ($1.85). For the next fiscal year, analysts expect that the firm will post earnings of ($1.18) per share, with EPS estimates ranging from ($1.35) to ($1.01). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Apollo Endosurgery.

Apollo Endosurgery (NASDAQ:APEN) last released its earnings results on Tuesday, August 1st. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.40). Apollo Endosurgery had a negative return on equity of 46.30% and a negative net margin of 29.63%. The business had revenue of $17.14 million for the quarter.

Several equities analysts have commented on the stock. Zacks Investment Research raised shares of Apollo Endosurgery from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Thursday. Northland Securities reissued a “buy” rating on shares of Apollo Endosurgery in a research report on Friday, October 27th. ValuEngine cut shares of Apollo Endosurgery from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 3rd. Roth Capital assumed coverage on shares of Apollo Endosurgery in a research report on Wednesday, August 2nd. They set a “buy” rating and a $10.00 target price on the stock. Finally, Craig Hallum assumed coverage on shares of Apollo Endosurgery in a report on Monday, July 24th. They issued a “buy” rating and a $11.00 price target on the stock. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Apollo Endosurgery has a consensus rating of “Buy” and an average target price of $9.44.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/03/zacks-analysts-expect-apollo-endosurgery-inc-apen-will-announce-earnings-of-0-29-per-share.html.

Apollo Endosurgery (NASDAQ APEN) traded down $0.09 during trading on Friday, hitting $4.25. 47,029 shares of the stock were exchanged, compared to its average volume of 57,683. The company has a current ratio of 2.54, a quick ratio of 2.00 and a debt-to-equity ratio of 0.58.

Apollo Endosurgery Company Profile

Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.

Get a free copy of the Zacks research report on Apollo Endosurgery (APEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apollo Endosurgery Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery Inc and related companies with MarketBeat.com's FREE daily email newsletter.